Prolonged Diabetic Ketoacidosis Associated with Sodium–Glucose Cotransporter-2 Inhibitors: A Review of Postmarketing Cases

Daniel Woronow,Christine Chamberlain,Monika Houstoun,Monica Muñoz

DOI: https://doi.org/10.1016/j.eprac.2024.04.012

IF: 3.701

2024-05-01

Endocrine Practice

Abstract:Objective To describe reported cases of prolonged or relapsed ketoacidosis (KA) in adults with type 2 diabetes receiving treatment with Sodium–Glucose Cotransporter-2 (SGLT2) inhibitors. Methods We performed a search of the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and medical literature, to identify our case series and to characterize cases of prolonged KA, relapsed KA, or persistent ketonemia, persistent ketonuria and/or persistent glucosuria in adults receiving SGLT2 inhibitors. Results The FDA identified 29 unique cases of prolonged or relapsed KA, as well as related terms persistent ketonemia, persistent ketonuria and persistent glucosuria, in patients receiving SGLT2 inhibitors through July 26, 2022. The patients ranged in age from 26 to 85 years. Treatment duration of KA ranged from 3 to 20 days. There were 7 cases of relapsed KA when insulin was reduced or transitioned to subcutaneous route. Arterial pH value was 7.0 or below in 4 patients and the median pH was 7.1. Associated factors for prolonged or relapsed KA included surgery, decreased caloric intake, and ketogenic/carbohydrate restricted diet. 62% of the patients were taking 3 or more glycemic control medications including the SGLT2 inhibitor. All patients with sufficient follow-up information recovered. Conclusion Although KA is well-known risk associated with SGLT2 inhibitors, this case series demonstrated the potential for prolonged or recurrent KA events with serious outcomes. These cases informed updates to FDA's prescribing information to inform prescribers of this risk.

endocrinology & metabolism